View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

PROMOTIECOMMISSIE Promotor: Prof.dr. H.L.A Janssen Overige leden: Prof.dr. E.W. Steyerberg Prof.dr. Th. Stijnen Dr. R.A. de Man
Voor Hans, Katrine en Rasmus
Page 1: Statistical Models of Treatment Eff
Page 4 and 5: ISBN: 978-90-8559-069-9 © Bettina
Page 9 and 10: CONTENTS Chapter 1. Introduction 11
Page 13: Cha pter 1 Introduction
Page 16 and 17: Chapter 1 14 Epidemiology Worldwide
Page 18 and 19: Chapter 1 16 Prediction models with
Page 20 and 21: Chapter 1 18 standard method fails
Page 22 and 23: Chapter 1 20 The extended non-linea
Page 24 and 25: Chapter 1 22 References 1. Blumberg
Page 27: Cha pter 2 Prediction of response t
Page 30 and 31: Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33: Chapter 2.1 30 been hepatitis B sur
Page 34 and 35: Chapter 2.1 32 HBV DNA decline The
Page 36 and 37: Chapter 2.1 34 Figure 2 continued.
Page 38 and 39: Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41: Chapter 2.1 38 DNA was observed in
Page 42: Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47: Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49: Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51: Chapter 2.2 48 patient subgroups wa
Page 52 and 53: Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55: Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Page 153 and 154:
where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Appendix Discriminant analysis usin
Page 175:
Cha pter 4 Statistical models of ea
Page 178 and 179:
Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181:
Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183:
Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185:
Chapter 4.1 182 Figure 1.
Page 186 and 187:
Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189:
Chapter 4.1 186 suppression in seru
Page 190 and 191:
Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194:
Cha pter 4.2 Viral dynamics during
Page 195 and 196:
INTRODUCTION Viral dynamics during
Page 197 and 198:
Viral dynamics during tenofovir the
Page 199 and 200:
Page 201 and 202:
log HBV DNA (copies/mL) 10.0 9.0 8.
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 211 and 212:
Chap ter 4.3 Modelling of early vir
Page 213 and 214:
INTRODUCTION HBV viral kinetics dur
Page 215 and 216:
HBV viral kinetics during PEG-IFN 2
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229:
Page 233 and 234:
SUMMARY AND CONCLUSION Summary and
Page 235 and 236:
Summary and conclusion 233 The mode
Page 237 and 238:
Summary and conclusion 235 The infe
Page 239:
Summary and conclusion 237 Early st
Page 243 and 244:
SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246:
Samenvatting en conclusie 243 Er we
Page 247 and 248:
Samenvatting en conclusie 245 Data
Page 249 and 250:
Samenvatting en conclusie 247 Behan
Page 253:
Dan kwoord
Page 256 and 257:
Dankwoord 254 Lieve Marion en Margr
Page 259 and 260:
BIBLI OGRAPHY Bibliography 257 1. K
Page 261 and 262:
Bibliography 259 Interferon-ribavir
Page 263 and 264:
Bibliography 261 Long term clinical
Page 265 and 266:
Bibliography 263 Flares in chronic
Page 267 and 268:
Bibliography 265 Genetic characteri
Page 269:
Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?